News

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.

Valeant chief Pearson won't be scared off by M&A 'bubble'

Valeant CEO J. Michael Pearson is plenty familiar with the pharma M&A space; after all, he's made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happening left and right in the sector, some of pharma's recent acquisitions "are not going to work."

Merck's Keytruda, BMS' Opdivo score European nods to keep immuno-oncology race blazing

Merck's Keytruda gained some regulatory ground in Europe on Friday, nabbing a melanoma recommendation that Opdivo snagged last month. But Opdivo continued to charge ahead, too, winning a nod in lung cancer to help preserve its lead.

Celgene's next-gen psoriasis drug dissed by German cost watchdog

Celgene's Otezla has hit a snag with the notoriously difficult German cost watchdog IQWiG, which said it just doesn't see the added benefit over treatments already on the market.

England's Cancer Drugs Fund keeps Bayer's Stivarga, axes Eisai and Lilly meds

England's Cancer Drugs Fund has drawn a hard line when it comes to its list of covered meds, axing cancer treatments despite pushback from drugmakers. But Bayer scored a victory for its cancer med Stivarga, getting the fund to reverse its decision and keep the drug on its list even as rival companies lose similar battles.

Want the U.K.'s NHS to quickly adopt new products, drugmakers? There's an office for that

Drugmakers want market access and reimbursement for their new products as fast as possible, and now, the U.K.'s National Institute for Health and Care Excellence is setting up an office with the same goal.

Endo sews up $9.2B financing for Par Pharma buyout

Earlier this week, Endo inked a pact to nab Par Pharmaceutical for $8 billion. But to do that, it'll need a loan, and it's agreed to a $9.275 billion loan package to back the acquisition.

CVS Health gets more drug pricing clout with $12B deal for Omnicare

Get ready for more of a squeeze on drugs used by seniors. CVS Health agreed to pay $12.7 billion for the pharmacy services company Omnicare, which specializes in assisted living and long-term care facilities.

Report: Cadila next in line for injectables bulk-up as it nears deal for Claris

India's Cadila Healthcare has emerged as the leading horse in a race to acquire the generic sterile injectables business of Claris Lifescience, and it's reportedly putting the finishing touches on a deal.

Aspen unloads $301M worth of meds to fuel expansion abroad

South Africa-based Aspen Pharmacare is looking to expand its global footprint, and the company is selling off two of its pharma portfolios to India's Strides Arcolab for a combined $301 million to lighten its load and put extra cash in the pot as it gears up for international growth.

Novo, Baxter spar over hemophilia patent amid ITC probe

Baxter said back in March that Novo Nordisk's recently launched hemophilia med infringed some of its patents, spurring an investigation from the U.S. International Trade Commission. But the Danish drugmaker doesn't see what all the fuss is about.

German cost watchdogs look askance at uniQure's $1.4M gene therapy

German cost-effectiveness watchdogs aren't among pharma's favorite people. Since lawmakers instituted a tough price-setting process, state officials have questioned the benefits of one new drug after another--to the point where some drugmakers decided not to launch there at all.

ProPublica: Safety questions over GSK's Advair linger after years on the asthma throne

U.S. regulators gave GlaxoSmithKline's Advair the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $8 billion in annual sales. But even after all these years, whether Advair poses a higher risk of asthma-related death remains unclear, ProPublica says.

Hep C landscape shifts again as BMS combo nabs breakthrough tag

Gilead Sciences and AbbVie caught a break for their hepatitis C treatments when the FDA rescinded breakthrough designations earlier this year for potential competitors being developed by Merck and Bristol-Myers Squibb.

J&J promises new uses for old meds to keep pharma sales flying high

Johnson & Johnson is riding high on strong sales for standout meds, but some slowdown could be on the horizon as competition increases for its top-selling drugs. And J&J is not going down without a fight, planning to roll out new versions of old meds to keep its pharma numbers in tip-top shape.

Should Pfizer snap up GSK? Well, a megadeal could speed up a split

Pfizer needs to make a deal--or several. It's obviously amenable to another megamerger, given that it tried to snap up AstraZeneca for more than $100 billion last year. So why not GlaxoSmithKline?

Report: Valeant in talks to buy Egypt's Amoun for up to $800M

Valeant's next pickup could come from the Middle East, where it's reportedly in deal talks with one of Egypt's largest drugmakers, Amoun.

The root of Orexigen's Contrave data blunder: CEO's 'I have to see it' choice

A couple of years back--before Orexigen's recent data leak landed it in hot water with regulators, researchers and marketing partner Takeda--CEO Mike Narachi said he believed data from a large cardiovascular outcomes study should be kept among "a small team." But he also believed he should be on that team.

Actavis wins more hearts on Wall Street as 'top 4' Morgan Stanley pick

Bill Ackman may be selling down the Actavis share he acquired when his plan to force an Allergan sale to Valeant failed. But for other investors, now's a good time to buy the Dublin drugmaker's stock, as far as Morgan Stanley is concerned.

Can Baxalta deliver on its big growth promises? Baxter says yes

As Baxter prepares to spin off its biopharma unit into new drugmaker Baxalta, it's touting strong, independent futures for both companies. But just how strong does Baxter expect its fledgling Baxalta to be?